JP2010511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511632A5
JP2010511632A5 JP2009539527A JP2009539527A JP2010511632A5 JP 2010511632 A5 JP2010511632 A5 JP 2010511632A5 JP 2009539527 A JP2009539527 A JP 2009539527A JP 2009539527 A JP2009539527 A JP 2009539527A JP 2010511632 A5 JP2010511632 A5 JP 2010511632A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
nhc
pharmaceutical composition
nhs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009539527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/086188 external-priority patent/WO2008067566A1/en
Publication of JP2010511632A publication Critical patent/JP2010511632A/ja
Publication of JP2010511632A5 publication Critical patent/JP2010511632A5/ja
Pending legal-status Critical Current

Links

JP2009539527A 2006-11-30 2007-11-30 ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法 Pending JP2010511632A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86802406P 2006-11-30 2006-11-30
PCT/US2007/086188 WO2008067566A1 (en) 2006-11-30 2007-11-30 Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators

Publications (2)

Publication Number Publication Date
JP2010511632A JP2010511632A (ja) 2010-04-15
JP2010511632A5 true JP2010511632A5 (cg-RX-API-DMAC7.html) 2011-01-20

Family

ID=39468284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539527A Pending JP2010511632A (ja) 2006-11-30 2007-11-30 ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法

Country Status (4)

Country Link
US (1) US20100068301A1 (cg-RX-API-DMAC7.html)
EP (1) EP2086531A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010511632A (cg-RX-API-DMAC7.html)
WO (1) WO2008067566A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
US20130310421A1 (en) * 2012-05-18 2013-11-21 Temple University - Of The Commonwealth System Of Higher Education Treatment of amyloid beta amyloidosis
WO2014031586A2 (en) * 2012-08-20 2014-02-27 Tallikut Pharmaceuticals, Inc. Methods for treating cardiovascular diseases
RU2015138443A (ru) * 2013-03-14 2017-04-20 Шир Хьюман Дженетик Терапис, Инк. Способы лечения ангионевротического отека, опосредованного рецепторами брадикинина в2
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
ES2878405T3 (es) 2014-02-04 2021-11-18 Bioscience Pharma Partners Llc Uso de inhibidores de flap para reducir la lesión mediada por neuroinflamación en el sistema nervioso central
US10350223B2 (en) 2015-03-03 2019-07-16 Richard W. Yee Compositions and methods for treating ocular diseases
US20180177724A1 (en) * 2015-07-02 2018-06-28 The Regents Of The University Of California Site-targeted nano-liposomal nitroglycerin therapeutics
CN108434439B (zh) * 2018-01-23 2020-02-07 中国人民解放军总医院 钙网蛋白的医药用途
WO2020010236A1 (en) * 2018-07-06 2020-01-09 Yale University Methods and compositions for the treatment of amyloid-related disorders
CN109187832B (zh) * 2018-09-30 2021-07-30 华润三九医药股份有限公司 Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081138A (en) 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
DE3814504A1 (de) 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3900261A1 (de) 1988-05-31 1989-12-07 Bayer Ag Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate
US5204344A (en) 1989-08-22 1993-04-20 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5272145A (en) 1989-08-22 1993-12-21 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
DE3927931A1 (de) 1989-08-24 1991-02-28 Bayer Ag Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate
US5229516A (en) 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
DE4139751A1 (de) 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate
US5304563A (en) 1991-02-22 1994-04-19 Bayer Aktiengesellschaft 2-substituted quinolines, and their use in medicaments
DE4128681A1 (de) 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4226519A1 (de) 1992-08-11 1994-02-17 Bayer Ag 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate
US5288743A (en) 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
AP9400632A0 (en) 1993-04-29 1995-10-07 Zeneca Ltd Ether derivatives.
US5399699A (en) 1994-01-24 1995-03-21 Abbott Laboratories Indole iminooxy derivatives which inhibit leukotriene biosynthesis
US5512581A (en) 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
US5795900A (en) 1995-10-03 1998-08-18 Abbott Laboratories Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5668146A (en) 1995-10-03 1997-09-16 Abbott Laboratories Symmetrical bis-heteroarylmethoxyphenyliminoxyalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5714488A (en) 1995-10-03 1998-02-03 Abbott Laboratories Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis
US5691351A (en) 1996-02-06 1997-11-25 Abbott Laboratories Bis-(Heteroarylmethoxyphenyl)cycloalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5668150A (en) 1996-07-26 1997-09-16 Abbott Laboratories Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5783586A (en) 1996-10-01 1998-07-21 Abbott Laboratories Heteroarylmethoxyphenylthioalkyl carboxylates as inhibitors of leukotriene biosynthesis
AU768721B2 (en) 1998-04-15 2004-01-08 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
AU2002222910A1 (en) 2000-07-13 2002-01-30 Bristol-Myers Squibb Company Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070244128A1 (en) 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
JP5558716B2 (ja) 2005-11-08 2014-07-23 サーモディクス，インコーポレイティド 極薄フォトポリマーコーティング及びその使用
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor

Similar Documents

Publication Publication Date Title
JP2010511632A5 (cg-RX-API-DMAC7.html)
ES2448549T3 (es) Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
ES2260857T3 (es) Uso de compuestos de aminotiol para el tratamiento de trastornos neurologicos y nefrologicos y toxicidades terapeuticas.
ES2621141T3 (es) Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR
JP2010523599A5 (cg-RX-API-DMAC7.html)
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
BR112015023747B1 (pt) Uso de um composto antimicrobiano catiônico esteroide (csa) para a preparação de uma composição para tratar, reduzir, ou prevenir inflamação aguda ou crônica e/ou dor aguda ou crônica associada com uma doença ou um sintoma de doença
PT2275108E (pt) Preparação farmacêutica que compreende inibidor de dpp-iv e outro agente terapêutico de diabetes na forma concomitante ou combinada
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
IL260701B (en) Use of certain sgc stimulators and salts thereof in the preparation of medicaments for the treatment of nonalcoholic steatohepatitis (nash)
ES2356986T3 (es) Agentes antitumorales.
ES3036920T3 (en) Compounds for prevention and treatment of post-operative cognitive dysfunction
JPWO2006016695A1 (ja) Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
WO2015144965A1 (es) Preparación duradera de inyectable de melatonina estable a largo plazo
JP2025539895A (ja) 腎臓の疾患の治療におけるａｓｂｔ阻害剤
JP6458000B2 (ja) ガンマグルタミル回路調節のための方法および組成物
JP2016503421A (ja) 薬剤耐性癌細胞の阻害
ES3035147T3 (en) Method for treating cancers
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
ES2965179T3 (es) Derivado polimérico soluble en agua de venetoclax
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
EP4027996A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
ES2319877T3 (es) Metodo para inhibir la formacion de adherencias.
JP2019142815A (ja) 心不全改善剤
KR20240093600A (ko) 패혈증 치료를 위한 trpc6 억제 화합물